

P&T Motion History
Calcitonin Gene-Related Peptide Inhibitors (CGRP)- migraine prevention

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
atogepant eptinezumab erenumab fremanezumab galcanezumab rimegepant	Migraine Prevention After considering the evidence of safety and efficacy for the treatment of migraine prophylaxis, I move that atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab, and rimegepant are safe and efficacious for the treatment of their approved indications. These drugs can be subject to therapeutic interchange in the Washington preferred drug list, within respective modes of delivery and approved indications. Motion: Barkett 2nd: Barnes	August 13, 2025	NA	Yes	Passed unanimous
rimegepant ubrogepant zavegepant	Acute Migraine After considering the evidence of safety and efficacy for the treatment of acute migraine, I move that rimegepant, ubrogepant, and zavegepant are safe and efficacious for the treatment of their approved indications. Rimegepant, ubrogepant, and zavegepant can be subject to therapeutic interchange with each other in the Washington preferred drug list. Motion: Beste 2nd: Barkett	August 13, 2025	N/A	Yes	Passed unanimous

Bold = new this update

P&T Motion History
Calcitonin Gene-Related Peptide Inhibitors (CGRP)- migraine prevention

Bold = new this update

8/25/2025